|
|
Article: Orbus Pharma Inc. Announces Signing of a Three Way License, Sale of Marketing Authorisations and Manufacturing Agreement
- Article from:
- CCNMatthews Newswire
- Article date:
- November 6, 2006
CopyrightCopyright 2006 CCNMatthews Newswire. Provided by ProQuest LLC. (Hide copyright information)
|
TORONTO, ONTARIO--(CCNMatthews - Nov. 6, 2006) - Orbus Pharma Inc.
(TSX:ORB) ("Orbus") today announced that it has entered into an
agreement with Desitin Arzneimittel GmbH, ("Desitin") of Germany for
its immediate release 150mg, 300mg and 600mg tablets containing the
active ingredient oxcarbazepine (anti-epileptic). Also party to the
agreement is Orbus' partner in this drug development, Alfred
E.Tiefenbacher GmbH & Co. KG ("AET") of Germany.
The agreement provides for the ongoing relationship between Orbus,
AET and Desitin to utilize Orbus' immediate release Oxcarbazepine
formulations to obtain marketing authorizations throughout the
European Union, as well as in Switzerland, Romania, ...